Myasthenia gravis and endurance exercise.
This is the first report of a runner with myasthenia gravis who completed an ultra endurance event. Myasthenia gravis, a neuromuscular disease that usually results in skeletal muscle weakness, which worsens with exercise and strenuous aerobic exercise, is generally contraindicated. Our runner completed a 220-km, 5-day ultramarathon and presented with various symptoms including muscular skeletal weakness, cramps, generalized fatigue, unintelligible speech, involuntary eye and mouth movements, problems swallowing, food lodging in his throat, and problems breathing. Risk factors identified for exacerbations are running in extreme temperatures, prolonged runs (especially a distance of 30 km or more), running uphill, lack of sleep, and stress. The medical team was in the novel situation to look after a runner with myasthenia gravis and needed to be aware of the patient's condition, symptoms, and risk factors to safely care for him.
AAUT, Team Axarsport, Alicante, Spain.
Bernd Volker
BV
Scheer
Encarna
E
Valero-Burgos
Ricardo
R
Costa
D056352:Athletes; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003680:Deglutition Disorders / Q000209:etiology; D005221:Fatigue / Q000209:etiology; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009120:Muscle Cramp / Q000209:etiology; D018908:Muscle Weakness / Q000209:etiology; D009157:Myasthenia Gravis / Q000150:complications* / Q000188:drug therapy; D009759:Nystagmus, Pathologic / Q000209:etiology; D010807:Physical Endurance; D011241:Prednisone / Q000627:therapeutic use; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D012120:Respiration Disorders / Q000209:etiology; D012146:Rest; D012307:Risk Factors; D012420:Running; D013065:Speech Intelligibility
D002800:Cholinesterase Inhibitors; D005938:Glucocorticoids; D011729:Pyridostigmine Bromide; D011241:Prednisone